U.S. Inhalation Anesthesia Market To Reach $1.06 Billion By 2030

U.S. Inhalation Anesthesia Market Growth & Trends

The U.S. inhalation anesthesia market size is anticipated to reach USD 1.06 billion by 2030, growing at a CAGR of 6.1% during the forecast period, according to a new report by Grand View Research, Inc. The market's growth is attributed to the rising demand for shorter hospital stays and increasing surgical procedures. Inhalation anesthesia offers higher patient outcomes compared to intravenous anesthesia, as administering anesthetic agents through the respiratory tract allows for more controllable, effective sedation that is both cost-effective and safe.

Inhalation anesthesia creates a reversible state of unconsciousness and loss of sensation, making it essential for pain-free surgeries. It is widely used for general anesthesia in various surgical settings, especially in outpatient, pediatric, and needle-phobic patients. Inhalation anesthetics are also valuable in diagnostic procedures and can be utilized outside the operating room for ICU sedation or conditions such as status asthmaticus. In addition, agents such as nitrous oxide provide moderate sedation in dental settings.

According to the National Library of Medicine, around 40 to 50 million major surgeries are conducted annually in the U.S. Inhalation anesthesia is critical for cancer diagnoses and biopsies, offering comfort during these procedures. The National Cancer Institute estimates that in 2024, about 2,001,140 new cancer cases will be diagnosed in the U.S., including 14,910 cases in children and adolescents. This rising cancer incidence is expected to boost the demand for inhalation anesthesia, particularly in pediatric and adult oncology care.

 Request a free sample copy or view report summary: U.S. Inhalation Anesthesia Market Report

U.S. Inhalation Anesthesia Market Report Highlights

• Based on drug, the sevoflurane drug dominated the U.S. inhalation anesthesia industry, accounting for the largest revenue share of 75.5% in 2024. The demand is driven by its popularity in day surgery due to the quick attainment of deep anesthesia and faster recovery times.

• The isoflurane drug segment is expected to grow significantly over the forecast period.

• Based on application, the maintenance phase dominated the market with the largest revenue share in 2024. However, the induction phase is expected to grow at a significant CAGR over the forecast period.

• Based on end use, the hospitals segment led the U.S. inhalation anesthesia industry with the largest revenue share in 2024.

• The Ambulatory Surgical Centers (ASC) end use segment is expected to grow at the fastest CAGR of 7.0% over the forecast period.

• The growing number of surgical procedures, including orthopedics, ophthalmology, gastroenterology, ENT, cosmetic surgeries, urology, gynecology, and podiatry, in ASCs is expected to drive the demand for inhalation anesthesia in the coming years.

U.S. Inhalation Anesthesia Market Segmentation

Grand View Research has segmented the U.S. inhalation anesthesia market based on drug, application, and end use:

U.S. Inhalation Anesthesia Drug Outlook (Revenue, USD Million, 2018 - 2030)

• Sevoflurane

• Desflurane

• Isoflurane

• Others

U.S. Inhalation Anesthesia Application Outlook (Revenue, USD Million, 2018 - 2030)

• Induction

• Maintenance

U.S. Inhalation Anesthesia End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Ambulatory Surgical Centers (ASC)

• Others

List of Key Players in the U.S. Inhalation Anesthesia Market

• Baxter

• AbbVie Inc.

• Piramal Enterprises Ltd.

• Hikma Pharmaceuticals PLC

• Halocarbon, LLC

• Sandoz Group AG

• Fresenius Kabi AG